Skip to main content

Table 4 Change in the visual acuity every month from baseline till the last visit

From: Comparison Between Ranibizumab Biosimilar, Innovator Ranibizumab and Bevacizumab in a Real-World Situation

  RBZ (n = 69) (%) BEV (n = 66) (%) BSR (n = 67) (%) RBZ vs BEV
p value
BEV vs BSR
p value
RBZ vs BSR
p value
Month 1       
 Increased 22 (31.9) 18 (27.3) 27 (40.3) 0.68 0.36 0.60
 Stable 42 (60.9) 44 (66.7) 32(47.8)
 Decreased 5 (7.2) 4 (6.1) 8 (11.9)
 n 69 66 67    
Month 2       
 Increased 7 (10.1) 8 (12.1) 7 (10.4) 0.58 0.45 0.82
 Stable 57 (82.6) 49 (74.2) 56 (83.60)
 Decreased 5 (7.2) 9 (13.6) 4 (6.0)
 n 69 66 67    
Month 3       
 Increased 8 (13.6%) 7 (10.9) 11 (18.6) 0.90 0.15 0.16
 Stable 46 (78.0) 54 (84.4) 47 (79.7)
 Decreased 5 (8.5) 3 (4.7) 1 (1.7)
 n 59 64 59    
Month 4       
 Increased 6 (12.2) 2 (3.6) 4 (13.8) 0.67 0.44 0.77
 Stable 37 (75.5) 49 (89.1) 22(75.9)
 Decreased 6 (12.2) 4 (7.3) 3 (10.3)
 n 49 55 29    
Month 5       
 Increased 8 (18.6) 4 (8.5) 3 (16.7) 0.03 0.18 0.63
 Stable 35 (81.4) 40 (85.1) 15 (83.3)
 Decreased 0 3 (6.4) 0
 n 43 47 18    
Month 6       
 Increased 6 (12.5) 3 (5.7) 1 (4.0) 0.34 0.65 0.64
 Stable 38 (79.2) 45 (84.9) 23 (92.0)
 Decreased 4 (8.3) 5 (9.4) 1 (4.0)
 n 48 53 25    
Last visit       
 Increased 8 (14.8) 6 (13.3) 2 (3.9) 0.92 0.70 0.79
 Stable 32 (59.3) 26 (57.8) 44 (86.3)
 Decreased 14 (25.9) 13 (28.9) 5 (9.8)
 n 54 45 51